ICYMI: EI-1071 for IPF Earns Orphan Drug Status
Sourced from: James Heilman, MD / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

ICYMI: EI-1071 for IPF Earns Orphan Drug Status

  According to an August 2022 news release from biotechnology company Elixiron Immunotherapeutics (“Elixiron”), EI-1071, a therapy for patients with idiopathic pulmonary fibrosis (IPF), recently earned Orphan Drug designation from…

Continue Reading ICYMI: EI-1071 for IPF Earns Orphan Drug Status
A Biomarker That Detects Alzheimer’s Disease Seventeen Years Before Outward Symptoms Appear
source: pixabay.com

A Biomarker That Detects Alzheimer’s Disease Seventeen Years Before Outward Symptoms Appear

A recent article in SciTechDaily explains that the many failures of newly created Alzheimer’s drugs are the result of clinical plaque tests that do not identify the disease in its…

Continue Reading A Biomarker That Detects Alzheimer’s Disease Seventeen Years Before Outward Symptoms Appear
Upadacitinib Shows Efficacy in Treating Ankylosing Spondylitis Refractory to Biologic DMARDs
Source: https://unsplash.com/photos/ZHys6xN7sUE

Upadacitinib Shows Efficacy in Treating Ankylosing Spondylitis Refractory to Biologic DMARDs

  Many patients with ankylosing spondylitis (AS) could be treated with biologics – in particular, biologic disease-modifying antirheumatic drugs (DMARDs). However, this line of treatment is not efficacious nor well-tolerated…

Continue Reading Upadacitinib Shows Efficacy in Treating Ankylosing Spondylitis Refractory to Biologic DMARDs
New Data Available on Paltusotine for Acromegaly
source: unsplash.com

New Data Available on Paltusotine for Acromegaly

  On September 9, 2022, researchers presented data at the European Neuroendocrine Association (ENEA) meeting. According to Yahoo! Finance, one such presentation centered around new safety and efficacy data from the…

Continue Reading New Data Available on Paltusotine for Acromegaly

Novel Gene Therapy Uses Brain Surgery to Achieve Results For Huntington’s Disease Patients, Part Two

As discussed in Part I of this article, a recent HDBUZZ publication featured a news item stating that due to several severe adverse events occurring during the initial AMT-130 trial…

Continue Reading Novel Gene Therapy Uses Brain Surgery to Achieve Results For Huntington’s Disease Patients, Part Two